NCT01942382View on ClinicalTrials.gov

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone palmitate

Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY